Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Carboplatin as Postoperative Adjuvant Therapy for Cholangiocarcinoma
ChiCTR-IPR-17010749Phase 4Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Feb 2017
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in cholangiocarcinoma (CCA) comparing Gemcitabine with Gemcitabine + carboplatin (2 arms). Primary endpoint: overall survival. Started Feb 2017; status: recruiting.
02
Drugs
gemcitabinecarboplatin
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on ChiCTR-IPR-17010749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17010749.